LIBRE LIFE LATEST NEWS

Abbott employees, a former Eli Lilly scientist, a healthcare lawyer and a university researcher have all appeared around Love My Libre. As Abbott challenges the Libreband trade mark, we ask whether these really are unrelated coincidences.

Abbott and Google plan one of the largest real-world metabolic health studies to date, with consumers buying the sensors and supplying the health data that builds AI they won't own. This isn't simply about Lingo: it could shape the future of CGM, who controls the intelligence behind our glucose data and ultimately how diabetes is managed.

Summer 2026 has brought important developments across FreeStyle Libre, from Libre 3 Plus and rapid growth in hybrid closed-loop use to new ADA evidence supporting Libre Duo, AI-powered Libre Assist and Abbott's wider move into connected health.

Abbott has secured CE mark approval for Libre Duo, its new dual glucose-ketone sensor designed for people with diabetes. The launch could mark one of the biggest diabetes safety developments since hybrid-closed loop systems became mainstream.

FreeStyle Libre news in March 2026 centres on a key change for UK prescriptions and several international developments.

Abbott receives warning letter for FreeStyle Libre sensors from the FDA following an inspection. The letter focuses on problems with Abbott's tests and verification of accuracy of their CGMs.

A recent update to the Libre 3 app in the US now enables users to snap their meal to learn how their glucose will change. At the same time the app has made it possible to see levels on a smartwatch.

Tidepool announce they will integrate with Abbott's Freestyle Libre portfolio for seamless cloud-to-cloud data.

We welcome news that will sensors can remain in place for MRI and CT scans and X-rays.